Mitchell Krucoff, Alessandro Spirito, Usman Baber, Samantha Sartori, Dominick J Angiolillo, Carlo Briguori, David J Cohen, Timothy Collier, George Dangas, Dariusz Dudek, Javier Escaned, C Michael Gibson, Ya-Ling Han, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Vijay Kunadian, Birgit Vogel, Shamir R Mehta, David Moliterno, Gennaro Sardella, Richard A Shlofmitz, Samin Sharma, Philippe Gabriel Steg, Stuart Pocock, Roxana Mehran
BACKGROUND: The optimal antiplatelet regimen after percutaneous coronary intervention (PCI) in patients with peripheral artery disease (PAD) is still debated. This analysis aimed to compare the effect of ticagrelor monotherapy versus ticagrelor plus aspirin in patients with PAD undergoing PCI. METHODS: In the TWILIGHT trial, patients at high ischemic or bleeding risk that underwent PCI were randomized after 3 months of dual antiplatelet therapy (DAPT) to aspirin or matching placebo in addition to open-label ticagrelor for 12 additional months...
March 6, 2024: American Heart Journal